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Abstract
We investigated in meso crystallization of membrane proteins to develop a fast screening technology which combines
features of the well established classical vapor diffusion experiment with the batch meso phase crystallization, but without
premixing of protein and monoolein. It inherits the advantages of both methods, namely (i) the stabilization of membrane
proteins in the meso phase, (ii) the control of hydration level and additive concentration by vapor diffusion. The new
technology (iii) significantly simplifies in meso crystallization experiments and allows the use of standard liquid handling
robots suitable for 96 well formats. CIMP crystallization furthermore allows (iv) direct monitoring of phase transformation
and crystallization events. Bacteriorhodopsin (BR) crystals of high quality and diffraction up to 1.3 A˚ resolution have been
obtained in this approach. CIMP and the developed consumables and protocols have been successfully applied to obtain
crystals of sensory rhodopsin II (SRII) from Halobacterium salinarum for the first time.
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Introduction
Although one third of a cell’s proteome represents membrane
proteins, they constitute a distinct minority with regard to known
3-dimensional structures at atomic resolution. Methods developed
for soluble protein crystallization might be often inefficient for
membrane proteins. This situation is especially bothersome as the
natural entry points to a cell are membrane proteins and their
assemblies: The lack of knowledge of membrane protein structures
translates directly into lack of knowledge of this single most
important group of biomedical targets and their mechanisms of
activity.
The small number of membrane protein structures known can
be directly traced back to problems in obtaining membrane
protein crystals for structural investigations. Membrane proteins
are difficult to crystallize using the methods that had been
developed and very successfully applied for soluble proteins. For
these proteins, the employment of the currently widely used
automated dispensing systems to set up vapor diffusion crystalli-
zation experiments [1], and the availability of thousands of pre-
made crystallization solutions boosted the number of successful
crystallization projects. Obviously, the multitude of different
conditions does not simply reflect the requirement to decrease
the solubility of the protein to induce crystallization, but the
necessity to stabilize certain states of the target protein by
interaction with components of these screens [2]. For detergent-
solubilized membrane proteins, similar progress has not been
made. Clearly, better methods for crystallization or better screens
or both are required to increase the chance to obtain well
diffracting membrane protein crystals.
The development of the lipidic cubic phase (LCP) crystallization
[3,4] introduced a new approach using monoolein-water based
mesophases [5] that accommodate membrane proteins better than
the conventional water-detergent systems: designed as a batch
method, the classical in cubo crystallization experiment is
cumbersome to perform [3]. It requires extensive manual labor
like weighing of mg quantities of monoolein and salt for every
single crystallization experiment. This is detrimental to high
throughput screening of available conditions and excludes the
application of automated liquid handling systems. Attempts to
increase the throughput of cubic phase batch crystallization
procedures by the use of special equipment that allows dispensing
of a premixed monoolein-protein-water paste [6,7] have been used
but high costs for the required extra dispensing system are
involved.
In contrast to the method that emphasizes active mixing [8] and
subsequent dispensing of a paste of meso phase either manually by
a syringe or with special dispensing systems, the pioneer
experiments [3] imply that no active mixing of aqueous protein
solution and dry monoolein is required to obtain the cubic phase
with embedded membrane protein. Another major difference
between these approaches is the way by which crystallization is
induced: when using protein-monoolein paste [8] this is achieved
by adding a precipitating (additive) solution, whereas the approach
in the Landau method was the addition of solid salt in order to
lower the free water content. In our method, the protein
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incorporation into the lipidic phase occurs passively (Figure 1),
whereas the crystallization is induced by increase of the protein
and the additive (precipitant) concentration through dehydration
by vapor diffusion.
As shown in the simplified phase diagram of monoolein (MO)/
water at room temperature (Figure 2), these lipids – besides the
cubic phase – form additional types of phases depending on the
water:lipid ratio. In the presence of certain concentrations of PEG
or Jeffamine [9–11] the formation of a dispensable sponge phase
containing monoolein is favored. The requirement to use certain
compounds to obtain this dispensable phase unfortunately limits
the scope of this approach and compares unfavorably with the
several thousands of different conditions that are used for the
crystallization of soluble proteins. While membrane protein
crystals can be obtained with different meso phases of the phase
diagram, it is inherent to batch and the sponge phase methods to
miss part of the space where high-quality crystals may form.
We therefore sought to develop a more flexibly applicable
method for crystallizing membrane proteins in meso. A superior
approach should (i) employ the equipment for high-throughput
screening already in use for the crystallization of soluble proteins,
which (ii) consequently requires to avoid the necessity to handle
highly viscous lipids, it should (iii) allow to utilize the multitude of
screening conditions commercially available to accommodate the
hydrophilic parts of the membrane protein, (iv) embed the
membrane part into a meso phase, (v) allow for controlled change
of concentration by dehydration of the protein-lipid mixture to
target specific meso phases, and (vi) should require only small
quantities of protein but should allow to grow crystals in
a timeframe of days to weeks.
We have developed protocols and materials to meet these
demands by combining the in meso principle with vapor diffusion
into a new method for controlled in meso phase crystallization
(CIMP) of membrane proteins.
Figure 1. Monoolein/water self-organization into mesophase: time course of mesophase formation. 900 nl water was added to a protein
well of a crystallization micro plate coated with 132 mg monoolein (MO). The optical properties of the forming phases were examined under
a polarization microscope over time. A, t = 1 min, B, t = 5 min C, t = 21 min, D, t = 22 min, E, t = 39 min Note: Arrows indicate the lower boundary of
the forming isotropic meso-phase.
doi:10.1371/journal.pone.0035458.g001
Figure 2. The monoolein/water isotherm at 226C. With increasing water content, the layered lamellar phases (Lc, La), cubic phases (Ia3d, Pn3m)
and the phase Pn3m + water are formed [5]. The transition from lamellar phase to cubic phase can be monitored by the optical property of the phase
(loss of birefringence, see Figure 1). The depiction of the phases has been adapted from M. Caffrey [33]. The water content required for the formation
of the individual phases can be targeted by vapor diffusion and addition of diluted screen solution as indicated (e.g. 1/1 means undiluted and 1/4
means the dilution of screen solution by a factor of 4).
doi:10.1371/journal.pone.0035458.g002
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Results
Concept of CIMP crystallization
We investigated the well established crystallization of BR [12]
and the also previously crystallized halorhodopsin [13] to establish
suitable setup and starting parameters for a fast screening method
for in meso crystallization of membrane proteins by vapor diffusion.
The obtained procedures and parameters for the experiment were
successfully tested by crystallizing the so far uncrystallized sensory
rhodopsin II from H. salinarum. The color of the rhodopsins allows
direct monitoring of the protein distribution in the meso phases.
Detrimental effects of crystallization conditions on protein stability
are detectable as loss of protein color due to release of
chromophor. In order to allow the use of available liquid handling
robotics for an automated reaction setup, we precoated the protein
wells of crystallization microplates with monoolein lipid, dried the
lipid and stored the plates in the absence of oxygen at 220uC after
sealing under nitrogen.
At 22uC, the solid monoolein self-organizes with water into
isotropic meso phase within 20–40 minutes. This self-organization
into isotropic cubic phase can be observed optically as a loss of
birefringence (Figure 1A–E). The isotropic cubic phase Pn3m
consists of a bi-continuous bilayer that separates two channel
systems of aqueous phase (Figure 2, meso phase structure,
indicated by blue coloring). The membrane-like bilayer of
monoolein is locally 2-dimensional like a cell membrane and
therefore allows the incorporation of membrane proteins, but it
extends continuously through space and therefore supports
diffusion of the protein in three dimensions. Crystallization of
embedded membrane protein is thought to occur upon formation
of lamellar phase from cubic phase [12,14]. In principle, this
approach allows the accommodation of the hydrophobic regions
of the membrane protein in an almost natural way into the bilayer.
The hydrophilic regions of the protein exposed to the aqueous
phase (water channels on both sides of the bilayer) are
accommodated by suitable buffer compositions, which must be
determined by buffer screening as it is the case for soluble proteins.
In vapor diffusion experiments, a droplet of a volume of protein
solution mixed with a volume of a solution containing a precip-
itating agent is equilibrated against a larger reservoir of the
undiluted precipitating agent to achieve super saturation by
transfer of water from the protein droplet to the reservoir through
the vapor phase. The final volume of the protein droplet is
determined to first approximation by the equality of precipitating
agent concentrations in the condensed phases. Therefore, the final
volume of the crystallization droplet is determined by the amount
of precipitating agent added. During equilibration the reduction of
the protein droplet’s volume leads to an increase of protein
concentration (s. curve K = 0 in Figure 3B).
In our approach, equilibration by vapor diffusion in the
presence of monoolein not only allows varying the expected final
protein concentration but also the total amount of water in
equilibrium with monoolein. The latter determines the type of
meso-phase, whereas the former determines, by the Nernst
partition law, the distribution of protein between the aqueous
and the forming meso-phase. Decreasing amount of available
water forces the lipidic meso-phase phase to adopt a meso phase
structure with less water (Figure 2). Decreasing amount of
available water also forces the protein into the meso-phase. In
the limiting case of the total disappearance of the aqueous phase,
all protein must be incorporated into the lipidic phase.
If such an experiment is performed, transformation of meso
phases and integration of the membrane protein into the lipidic
phase are observed, and under suitable conditions this leads to the
formation of protein crystals within the meso phase (Figure 4).
Specific meso phases can be targeted by sets of such experiments
with different final hydration levels, e.g., by employing undiluted
(1:1) and 1:4 and 1:7 dilutions of screening solution (Figure 2,
Figure 3). Thereby, the explicit determination of the phase
diagrams of monoolein, which depend on the used precipitant and
detergent as well as other additives, can be avoided.
The distribution of protein between the aqueous and the lipidic
phase under our standard conditions was measured and
calculated, resulting in partitioning constants K, whereas a high
K value indicates a high degree of protein incorporation into the
lipidic phase. Figure 3A shows that for partitioning constants K.5
the expected incorporation into the lipidic phase exceeds the 90%
threshold for water contents smaller than 40%. Furthermore, the
protein concentration in the supernatant will not exceed the
concentration of the protein in the protein sample used in the
experiment if the removal of water from the experiment is slower
than the speed of incorporation of the protein into the lipidic
phase (Figure 3b). If one of these conditions is not met
precipitation of the protein from the aqueous solution in the
crystallization experiment would be possible. For partitioning
constants K,0.2 the incorporation becomes less than 30% of total
protein, which would severely impair the utility of CIMP
crystallization (Figure 3b). For bacteriorhodopsin, apparent
partitioning constants in the range of 13 to 130 were found by
measuring the protein concentration in the aqueous supernatant.
In the case of slow integration into the lipidic phase or a small K
value, the increase of the protein concentration during equilibra-
tion by vapor diffusion will at most reach the values calculated for
ideally diluted conditions with K = 0 (Figure 3b). In general, it is
expected that an increase in protein concentration increases the
speed of mass transfer of protein into the meso phase and thereby
limits the increase of the protein concentration in the aqueous
phase during the removal of water by vapor diffusion.
When a high protein concentration is used or when the mass
transfer from the aqueous supernatant into the surface of the
lipidic phase is much faster than the diffusion of the protein within
the cubic phase, crystallization may occur before the protein is
homogenously distributed within the meso phase (Figures 5B, S1).
In principle, this allows screening different protein concentrations
within one experiment.
Parameters and phases in CIMP crystallization
The typical CIMP crystallization experiment has three distinct
phases, i) the swelling phase when solid monoolein takes up
aqueous solution (Figure 1) to form cubic phase, ii) the
equilibration phase during which the meso phase is dehydrated,
and iii) the incubation phase when the hydration level of the meso
phase remains constant and the only remaining process is protein
diffusion and possibly crystallization (e.g., Figure 5D).
To start the swelling phase (monoolein hydration), we first tested
the solid monoolein in the crystallization plate with various
volumes of protein solution. The solid monoolein with 86% water
transforms completely into isotropic phase within 40 minutes
(Figure 1A–E). If a solution of detergent-solubilized membrane
protein is used, the phase transformation time is considerably
prolonged and variable, even in the presence of excess volume of
aqueous solution. The competing reaction, the uptake of
monoolein by the aqueous solution, is typically of minor
importance because of the low solubility of monoolein in water.
For the precoated plates with 132 mg (29 mg) of monoolein, we
found a volume of 900 nl (200 nl) (Figure S2) of aqueous, i.e.
protein plus screening solution sufficient to completely wet and
hydrate the surface of the solid monoolein at 22uC. Although the
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actual minimal volume varied depending on the composition of
the protein solution, we found 900 nl (200 nl) to be sufficient in all
cases to obtain isotropic (cubic) mesophase.
The immediate addition of screening solution to the crystalli-
zation well after dispensing highly concentrated protein solution
onto the dry monoolein has been evaluated with BR. This
modified procedure would allow one to avoid plate handling steps
Figure 3. The effect of dilution for different partitioning constants K. A, Fraction of total protein incorporated into lipidic phase calculated
for different partitioning constants as a function of water content (upper abscissa). B, Remaining concentration of protein in the aqueous phase
(supernatant including the water content of the mesophase) relative to sample concentration calculated for different partitioning constants as
a function of water content (upper abscissa). The lower abscissa gives the dilutions of the screening solution added to perform the standard
experiment targeting the hydration level indicated on the upper abscissa. Dilution factor 1 refers to undiluted screening solution added, factor 2
refers to a 1:2 diluted screening solution etc. Standard experiment: 132 mg monoolein plus 450 nl protein solution (sample) plus 450 nl undiluted or
diluted screening solution to be equilibrated against undiluted screening solution in the well reservoir. Calculations are based on a partitioning
model, where the protein is assumed to be monomeric in both phases with K = Clip/Caq, ,where C (molality) refers to protein concentration in the
lipidic or aqueous phase. Courses of lipid-incorporated and protein remaining in the aqueous phases in A and B are depicted for K values between
0 and 125 as indicated in the insets.
doi:10.1371/journal.pone.0035458.g003
Figure 4. CIMP crystallization of BR (H. salinarum). A, Crystals from high excess water crystallization condition after 2 weeks (expected hydration
level 75%). Ammonium sulfate was used as precipitant. Crystal size is approximately 11 mm. B, Crystals from excess water crystallization condition
after 5 days (expected hydration level 60%). Na/K phosphate was used as precipitant. Crystal size is approximately 140 mm. C, Crystals from cubic
phase crystallization conditions after 10 weeks (expected hydration level 43%). Na/K phosphate was used as precipitant. Crystal size is approximately
100 mm. D, Crystals from cubic/lamellar phase crystallization conditions after 14 weeks (expected hydration level 30%). Na/K phosphate was used as
precipitant. Crystal size is approximately 200 mm.
doi:10.1371/journal.pone.0035458.g004
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and to skip the swelling phase and save 3 hours of incubation time.
Colored crystals of BR were indeed obtained but they were tiny
(,5 mm) and of minor quality (data not shown). In further
experiments, we observed that highly concentrated protein
solutions can precipitate under these conditions, and induce
crystallization of membrane protein in aqueous solution
(Figure 4A). Therefore, we started experimental series generally
with a swelling time of three hours prior to adding the screening
solution to the protein well.
In the equilibration phase (monoolein dehydration), the mixture of
protein and screening solution in the presence of monoolein is
equilibrated against screening solution in the reservoir. Within
days to weeks, equilibration of the vapor diffusion experiment
occurs. The incubation phase (protein diffusion) starts once the
equilibrium condition of the vapor diffusion experiment has been
reached. Diffusion-controlled crystallization of the protein in the
lipidic matrix may occur within weeks to months (Figure 4C, 4D,
5D). In any case, we did not observe a crystallization time that
exceeded 14 weeks. The workflow of the developed in meso
crystallization method is very similar to the procedure of a regular
vapor diffusion setup (Figure S2).
CIMP crystallization experiments with Bacteriorhodopsin
and Halorhodopsin
BR was used as the model protein to establish and optimize the
CIMP crystallization method. The optimization of the crystalliza-
tion conditions was based on the information that BR is
crystallizable using phosphate as dehydrating agent. In a grid
screen (pH 4.5 to 8.5, 0.5 M to 4.0 M phosphate) [3] with 8 plates
we varied the protein concentrations, the initial droplet volume
and, by dilution, the concentration of screening solution in the
initial droplet. Twinned crystals that diffract to a resolution of
1.3 A˚ were obtained (Figures S3, 4B). Data obtained at the ESRF
in Grenoble (ID29) were useful to a resolution of 1.45 A˚
(Rmerge = 0.065) with a Mean (I/sigI) of 3.3 for the resolution
shell 1.54–1.45 A˚. As expected, no significant differences to the
known high-resolution structure of bacteriorhodopsin from also
twinned crystals (1C3W) [15] were observed.
Further crystallization experiments with other screens we
designed for the LCP method (salt versus pH, the CubicPhase I
grid screen, and PEG versus pH, the CubicPhase II grid screen)
and further salts failed for BR with the notable exception of
ammonium sulfate. With this salt, we obtained non-diffracting
crystals (Figure 4A) of cubic appearance (targeted phase Pn3m
with excess water, Figure 2). Crystals of this appearance had been
obtained earlier in the absence of mesophase also with ammonium
sulfate from aqueous solution of the protein. This condition is
known not to produce well diffracting crystals [16]. It is
noteworthy that these crystals can be obtained with neither
ammonium phosphate nor sodium/potassium phosphate. We
conclude that interactions between the salt and BR are required to
induce crystallization, an effect that has previously been proposed
in complete generality [2].
Although crystallization of BR has been streamlined to yield
high-quality crystals (Figure 4B, Figure S3), it can even be forced
to occur during the equilibration phase upon overnight incubation
of the experiment if conditions have been optimized accordingly
(Video S1). This allows continuous recording of the progress of the
crystallization experiment even though the obtained crystal size
appears to be adversely effected by the required continuous
illumination. This allowed for the first time to visualize and
document the complete course of membrane protein crystalliza-
tion in meso phase. The time-lapse movie revealed that (i) the
passive incorporation of BR into the mesophase generates a lateral
protein concentration gradient, (ii) transformation of cubic phase
occurs first where the protein and the detergent concentration is
highest, and that (iii) crystallization may occur at a protein
concentration that is visually undetectable by the red color of BR,
which indicates that here the amount of protein per area is much
lower than in the red colored region. These observations imply
that an optimal condition (ratio protein:monoolein:detergent)
exists, which may be more difficult to find in batch-LCP
crystallization approaches.
The same condition that allowed over-night LCP crystallization
of BR was applied to a different format: hanging drop vapor
diffusion crystallization using a sealing foil and a standard micro
titer plate (Figure S4). The same workflow as for sitting-drop
experiments described so far (Figure S2) was followed. Crystals of
BR of up to 50 mm in size were generated after 16 hours
incubation. Similar to the observation made in the time-lapse
Figure 5. CIMP crystallization applied to Sensory Rhodopsin II
(H. salinarum). SRII crystals from cubic phase using the precipitant
ammonium sulfate ((NH4)2SO4) are shown. A, First hit after 12 weeks
incubation time, expected final (initial) hydration level was 43% (87%).
4.0 M (NH4)2SO4 was used as precipitant. Crystal size is approximately
6 mm. B, First diffracting crystal obtained after 3 weeks incubation time,
expected final (initial) hydration level was 43% (87%). 3.3 M (NH4)2SO4,
50 mM malonate was used as precipitant. Crystal size is approximately
140 mm. C, Optimized crystallization condition, expected final (initial)
hydration level was 30% (87%). 3.3 M (NH4)2SO4, 600 mM malonate was
used as precipitant. D, Optimized crystallization condition, expected
final (initial) hydration level was 30% (87%). 3.3 M (NH4)2SO4, 50 mM
malonate was used as precipitant. Crystal size is approximately 180 mm.
doi:10.1371/journal.pone.0035458.g005
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movie (Video S1), crystals mainly grew in the periphery of MO/
protein droplets. The hanging drop variant seems to work equally
well as the sitting-drop method and may be used to further simplify
the procedure of LCP crystallization by CIMP crystallization.
A setup similar to BR was started in the sitting-drop mode for
halorhodopsin (HR) based on published crystallization conditions
[13]. Small crystals diffracting to a resolution of 8 A˚ were obtained
within the first three plates that were set up. Variation of the ß-
octylglycoside concentration by adding 1% (w/v) detergent to the
screening solution improved the crystal size to 0.27 mm (Figure
S1). Optimization of HR crystallization was not investigated
further.
CIMP experiment with H. salinarum Sensory Rhodopsin II
Instead, we investigated H. salinarum Sensory Rhodopsin II
(SRII), which had not been crystallized before. We failed to obtain
crystals using the crystallization conditions of the more stable
homologous protein from N. pharaonis [17–19]. Therefore, we
tested the effect of different compounds on solubility and stability
of the protein in detergent solution with a commercial pre-screen
assay kit. The protein was stable in four unbuffered respectively
neutral solutions (4.3 M NaCl, which is close to the purification
condition, 1.1 and 3.2 M ammonium sulfate, and 3 M Na/K
phosphate, pH 7.0), whereas in all other cases the protein
precipitated immediately or latest after one day. Consequently,
we set up trials in Na/KPO4 and ammonium sulfate (from 1.6 up
to 4.0 M) for crystallization in the CubicPhase micro plate.
After three months, crystals with a size of 5–10 mm appeared in
the highest concentration of ammonium sulfate (Figure 5A). In the
next setups, we combined the ammonium sulfate screen with
different additives by mixing it with commercial anion-, cation-,
PEG-based or the Optisalts screening suites by diluting the
precipitant with additive to obtain a final additive solution content
of 10% (v/v). After a two months incubation time, we could
identify sodium malonate from the Optisalts screen as the one
additive that led to improved crystal size.
Further optimization (fine screening) of protein concentration,
mixing ratio (dilution factor) and reservoir concentration led to
a reduction of the crystallization time to 3 days.
Best diffracting crystals (406406250 mm) have been obtained
after 10 to 17 days by equilibrating 450 nl protein solution (highly
pure protein preparation of 31 mg/ml with H. salinarum polar
lipids in a ratio 10:1 mol/mol protein) plus 450 nl of unbuffered
1.7 M (NH4)2SO4, 190 mM sodium malonate (1:2 dilution of the
reservoir solution) against 3.4 M (NH4)2SO4, 380 mM sodium
malonate in the reservoir. Data obtained at the ESRF, Grenoble
(ID 14) were useful to 3.5 A˚ (Rmerge = 0.129) with a Mean(I/sigI)
of 3.4 for the resolution shell 3.69–3.50 A˚. The structure SRII of
H. salinarum has been solved and will be published elsewhere.
Discussion
We have developed a novel LCP technology for controlled in
meso crystallization (CIMP) of membrane proteins which should
prove useful to overcome current limitations associated with
structural investigation of this type of proteins. CIMP has been
applied successfully to crystallize several integral membrane
proteins, and we report the crystallization of one of those: SRII
from H. salinarum, a previously uncrystallized light receptor. Major
problems in membrane protein crystallization employing tradi-
tional methods are caused by the low solubility of membrane
proteins that must be overcome by a detergent that increases the
amount of dissolved protein substantially without destabilizing it.
We resolve the solubility problem by the application of the vapor
diffusion method, which allows increasing the protein concentra-
tion by removing excess water through the vapor phase. This
advantage is also given for the dispensable sponge phase
crystallization approach [10], even though its applicability is
limited by the number of compatible screening solutions.
However, it is missing in the pioneering approach of Landau
and Rosenbusch [3]. With CIMP crystallization, the ratio of
membrane protein:meso phase is limited only by the amount of
protein (and detergent) that the mesophase can incorporate. CIMP
crystallization not only enables a very fast and complete screening
of the parameter space for crystallization in combination with
robotic systems, but also allows to reach parts of the parameter
space that are principally inaccessible by batch methods. CIMP
crystallization varies concentration of protein in the lipidic phase
and the precipitating agent in the aqueous phase within the
equilibration period of the experiment as typical for vapor
diffusion experiments, which is not the case for LCP crystallization
from pre-prepared protein-containing mesophase paste where
protein and additive concentrations hardly change at all.
Furthermore, the generation of a spatial gradient of protein
within one experiment is only possible with a method such as
CIMP that uses passive mixing. This is achieved by pre-incubation
of the solid monoolein with the protein solution for about 3 hours
(Figure S2, Video S1).
It should be noted, however, that all components of the protein
solution will be concentrated during the vapor diffusion experi-
ment [1], especially if a dilution scheme as described in Figure 3 is
applied. For example, in the case of halorhodopsin, the presence of
a second detergent is a critical parameter for crystallization
success. In such a case, however, where a certain additive needs to
be present, an adaption of this condition can be easily achieved by
including the additive in the diluted screening solution that is
added to the crystallization droplet.
The complex composition of aqueous solutions used in the
crystallization experiments implies that the simple phase diagram
of the monoolein/water system (Figure 1) insufficiently describes
the more complex system used here. In any real experiment, the
phase diagram of the aqueous monoolein system will be unknown
because, in addition to water and monoolein, also protein, buffer,
salt, detergent [20], and lipids [21] will be present and influence
the phase stability and transformation. Known phase diagrams
can only define starting parameters for the crystallization
experiments. Nevertheless, we found the monoolein-water phase
diagram sufficient to target the different mesophases by using
different dilutions of screening solution (Figure 3).
The recommended protocol (Figure S2, see also Material and
Methods) gives the extreme or best values of the experimental
parameters, e.g., with respect to the volume of the initial aqueous
phase of 450 nl+450 nl: the total volume of 900 nl per 132 mg
monoolein is the minimum required to obtain reasonable lipid
hydration, compactness and surface smoothness of the resulting
mesophase, which allows to detect even colorless crystals (Figure
S5A). The volume of protein solution can be increased at will to
increase the protein:monoolein ratio. The added volume of
screening solution, however, should be kept constant as it is an
optimal parameter that allows, for different dilutions of screening
solution, to target the different meso phases.
We found that our approach as outlined can be easily scaled
down to 29 mg of monoolein per experiment which corresponds
for the optimize crystallization conditions to a consumption of
1.6 mg of protein (100 nl; 16 mg/ml) per BR crystallization
experiment. BR crystals obtained under these conditions were
about 30 mm in size. Crystals of this dimension can be analyzed on
all micro-focus synchrotron sources. Experiments with 132 mg
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MO (7.2 mg protein, 450 nl solution) led to crystals of 200 mm in
length under the same conditions. However, our very early
experiments using 500 mg MO did not yield crystals larger than
200 mm. Therefore, the scalability of the crystal size that can be
obtained from LCP experiments seems to be limited.
In the described CIMP crystallization approach, the kinetics of
all processes before reaching equilibration is ultimately driven by
the equilibration through the vapor phase. In some cases, it may
be desirable to slow down equilibration to allow more time for the
protein to migrate within the mesophase. Although none of our
test proteins required this for crystallization, the equilibration of
the vapor diffusion experiment can be slowed down easily by
adding a layer (of, e.g. mineral oil) on top of the reservoir solution
[22,23].
Upon recording BR crystallization experiments through a mi-
croscope we observed that the colored protein becomes inhomo-
genously distributed within the mesophase (Video S1). Protein
crystallization was seen first in a region of low protein
concentration (Video S1, Figure S4), which seems to be ideal for
initiation of this event. We believe that crystal growth is supported
by continued supply of protein from regions of high protein
concentration. We regard it as one of the big advantages of the
CIMP method to have an inhomogeneous protein distribution
within the mesophase as this allows, in principle, to screen at any
point in time different protein concentrations within the same
experiment. The formation of a concentration gradient for the
membrane protein appears to be more pronounced the higher the
initial protein concentration was. It is noteworthy that such
gradients can also be observed in the classical mesophase
experiment with solid salt.
A major concern with regard to the crystallization of
temperature sensitive proteins is the required incubation temper-
ature of at least 18uC for monoolein phases [7]. But even for a less
stable mammalian GPCR, crystallization in mesophase was
reported [24,25]. Clearly, membrane proteins embedded in meso
phases exhibit an increased half-life compared to the detergent-
solubilized state [26]. Nevertheless, a reduction of the required
incubation temperature is desirable and may be attempted by
doping the mesophase with lipids like cholesterol or by the
exchange of the major component monoolein [26–28].
The experiments shown, e.g., in Figure 5D and Video S1 have
been repeated more than 20 times and always gave the same
results; moreover, CIMP crystallization has been performed with
different protein batches of BR and SRII and in different
laboratories with varying equipment (data not shown). Therefore,
we regard the reproducibility and robustness of CIMP crystalli-
zation as very high.
Currently the protein consumption per experiment with 29 mg
of monoolein requires 100 nl of protein solution whereas the paste
method requires 20 nl per 30 mg [7]. As, however, diluted protein
solution can be used for CIMP crystallization, the current
consumption of these methods is about equal when equal amounts
of protein per monoolein are targeted. In fact, the protein
consumption of CIMP crystallization can be considerably lower
because of the gradual increase of local protein concentration by
protein and vapor diffusion. We obtained crystals of bacteriorho-
dopsin with a size of 3–5 mm using concentrations as low as
1.6 mg/ml (0.7 mg per experiment with 132 mg monoolein) within
48 hours. Interestingly, the crystallization time can be also
considerably lower than for the paste method. We obtain crystals
deeply embedded into meso phase after 10 to 14 weeks (Figure 4
C,D) , whereas crystals close to or at the water/lipid phase
boundary form within hours (Video S1) or days (Figure 4B). We
suggest that the diffusion of protein molecules within the meso
phase is much slower than the incorporation of the protein into the
surface of the meso phase when using CIMP crystallization
employing an adequate setup. This would lead to the nucleation at
lower overall concentration of protein than observed for the paste
method. Crystal growth could be fed by protein from the aqueous
solution. In any case, such a setup should be realizable when
employing a diffusion barrier as described.
CIMP crystallization using precoated plates requires no steps
that cannot be easily implemented using standard robotics, which
is not the case for the LCP approaches reported so far. We believe
that the CIMP method can contribute to accelerate the progress in
crystallization and structure determination of membrane proteins.
Materials and Methods
Reagents, solutions, and crystallization microplates
96-well crystallization plates precoated with monoolein (Cubic-
Phase mplates) with 500 mg, 132 mg or 29 mg of monoolein per
experiment and screening suites (CubicPhase I, CubicPhase II,
Optisalt, Easy Xtal Pre-Screen Assay) as well as Ni-NTA Agarose
were obtained from Qiagen. Detergents were from Glycon.
Crystallization plates coated with 500 mg and 150 mg
monoolein were initially prepared by dispensing molten mono-
olein at 42uC. This dispensing procedure was found to be
unreliable for 150 mg coatings. Precoated plates from industrial
production with 132 mg or 29 mg are produced with CV values of
less than 5%.
Protein expression and purification
Bacteriorhodopsin (BR) was prepared as described previously
[29].
SRII was expressed in E. coli and purified in 4.0 M NaCl,
50 mM MES, pH 6, 0.05% DDM (n-dodecyl-ß-maltoside) as
described previously [30].
His-tagged halorhodopsin (HR) was expressed in H. salinarum.
The HR overexpressing L33 strain [31] was shaken under
illumination for 2–4 days at 120 rpm in a medium containing
1% (w/v) peptone, 4.3 M NaCl, 80 mM MgSO467H2O, 27 mM
KCl, 10 mM tri-NaCitratx2H2O, pH7.0. At OD600 nm 1–1.5,
shaking speed was reduced to 80 rpm for 2–4 days. Cells were
harvested and resuspended in 100 mM sodium phosphate buffer,
pH 7.2, supplemented with DNase I, and passed three times
through an EmulsiFlex-C3 homogenizer (Avestin). The insoluble
fraction which contains halorhodopsin was isolated by centrifuga-
tion (130,0006 g, 1 h, 4uC) and solubilized overnight at 4uC in
4.0 M NaCl, 50 mM MES, pH 6.0, 2% (w/v) DDM. The
solubilized membrane protein fraction was isolated by centrifuga-
tion (130,0006g, 1 h, 4uC) and the target protein purified by Ni-
NTA Agarose chromatography in 4.0 M NaCl, 50 mM MES,
pH 6.0, 0.05% (w/v) DDM. Detergent was exchanged by washing
extensively with 4.0 M NaCl, 50 mM MES, pH 6.0, 0.1% (w/v)
ß-octylglycoside. The protein was eluted by lowering the pH to
4.5. The protein was stored at pH 5.5–6.
Purified membrane proteins were concentrated by ultra-
filtration (Molecular weight cut-off 10 kDa) and filtered
(0.22 mm, Millipore) as described [32].
Determination of apparent partitioning K
Monoolein precoated plates were incubated with various
volumes of protein solution of known concentration. After
24 hours of incubation at 22uC the supernatant was separated
by aspiration and centrifuged at 20000 g for 10 minutes. The
protein concentration in the obtained supernatant was photomet-
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rically determined. The K value is calculated according to the
information given in the legend of Figure 3.
Optimized crystallization protocol (standard conditions)
Microplates precoated with 132 mg (29 mg) monoolein and
stored at 220uC were thawed at 22uC for 10 minutes. 450 nl
(100 nl) of protein solution per experiment is dispensed on top of
the MO coating to start MO swelling and the formation of cubic
phase. The plate is sealed and incubated at 22uC. After 3 hours,
450 nl (100 nl) of screening solution diluted, e.g., 1:4 (Figure S2)
are added to the experimental well and 75 ml of undiluted
screening solution is transferred to the reservoir wells. The resealed
plate is incubated at 22uC and monitored for progress (phase
transformation and crystal formation) at least once per week.
Crystallization experiments using plates precoated with 132 mg
MO were prepared manually or with Evo-100 Robot (Tecan),
plates precoated with 29 mg and foils precoated with 100 mg
monoolein were processed with a Mosquito robot (TTP-Labtech).
In foil-based hanging-drop crystallization, dry MO spots
(100 mg each) were hydrated with 300 nl BR solution, incubated
for 3 hours at 22uC on top of an empty standard 96-well micro
plate (droplets hanging under the foil); then, the foil was removed,
the precipitant solutions added to the micro plate wells, the foil
placed back on top of the plate and incubated at 22uC for
crystallization.
Monitoring of protein crystallization
The phase transformation of monoolein was monitored under
a microscope (SZX10, Olympus) for change in birefringence of the
mesophase. For colorless crystals, the discrimination between
speckles of lamellar phase and protein crystals becomes increas-
ingly difficult with decreasing size of crystals. Therefore, we choose
an UV-transparent material for the crystallization plates that allow
monitoring crystal formation and detection of salt crystals using
a fluorescence microscope (Figure S5).
Supporting Information
Figure S1 Crystallization of halorhodopsin (HR) from
H. salinarum by CIMP. Crystals 240 mm in size were obtained
from cubic phase condition after 3 days. The final MO hydration
level is estimated to be approximately 43%. The HR protein was
crystallized using a precipitant mixture of KCl and ß-Octylglyco-
side.
(TIFF)
Figure S2 Workflow for in meso crystallization by vapor
diffusion. The graphic flow scheme describes the standard
experiment. It covers the swelling phase (self -organization of the
mesophase) and the early equilibration phase starting with the
addition of screening solution to the reservoir (R, undiluted) and to
the protein droplet.
(TIFF)
Figure S3 Bacteriorhodopsin diffraction. Data were
collected at ID29 at the ESRF (Grenoble) from the crystal shown
in Figure 4B. The right panel shows a zoom into the region
marked by the grey insert in the left panel.
(TIFF)
Figure S4 Hanging-drop crystallization of BR by CIMP.
100 mg of monoolein was spotted onto the lower side of
hydrophobic and glue-free slots of a crystallization foil and
subjected to hydration by 300 nl of BR solution (16 mg/ml). For
swelling, the foil was placed over an empty standard 96-well
microtiter plate for 3 hours at 22uC with the MO/protein spot
hanging below the foil into the plate well. After incubation, the foil
was removed from the microtiter plate, 300 nl of screening
solution (2.8 M Na/K phosphate, pH 5.9) diluted 1:4 was added
to the MO/protein droplet and 50 ml of undiluted screening
solution was filled into the corresponding well of the microtiter
plate. The foil was placed back over the plate and incubated for
crystallization over night. A, Close-up to well number A1 of the
microtiter plate sealed with the crystallization foil. The purple
color represents BR protein and protein crystals. B, Close-up to
the MO/protein spot shown in A. BR crystals are visible in the
periphery of the spot in the area of low protein concentration. C,
Close-up to the upper third part of the spot shown in B. BR
crystals of up to approximately 50 mm are generated after
overnight crystallization. The bar indicates a size of 50 mm.
(TIFF)
Figure S5 Crystal Detection. Sensory rhodopsin crystals lost
the chromophore under certain conditions and after long
incubation. Colorless crystals with a size of 10–30 mm can be
clearly observed by optical microscopy (A) and epifluorescence (B).
(TIFF)
Video S1 Time course of CIMP crystallization of
bacteriorhodpsin (BR). For t = 14 hours, the experimental
progress was recorded (Olympus SZX10, Olympus camera DP20)
under constant cold illumination by glass fiber optics (Schott
KL1500, Osram 150 W, Settings: half light, power level 1) to
avoid uncontrolled changes in temperature. A brief script of what
the movie shows is provided: at t = 0, swelling of 150 mg
monoolein was initiated by dispensing of 450 nl BR protein
solution (16 mg/ml). At t = 3 hours, 450 nl of 1:4 dilution of
reservoir solution were added to the protein well and equilibrated
against undiluted reservoir solution (2.8 M Na/K phosphate,
pH 5.8). Swelling continues and passes into equilibration phase. A
BR protein concentration gradient from left to right can be clearly
observed by the intensity of the purple color (left: high BR
concentration; right: low BR concentration). At t = 6:30 hours, the
microscope is refocused. At t = 7:45 hours, a local collapse of the
cubic phase is observed in the centre of the well. After 10 hours,
first crystals become visible on the right, the area of lowest protein
concentration. At t = 10:30 hours, the movie zooms into the
crystallization area. Crystals keep on growing until the end of the
movie at t = 14 hours. The largest BR crystal visible in the time-
lapse movie is approximately 30 mm.
(AVI)
Acknowledgments
We thankfully acknowledge the ESRF Grenoble for allocating measure-
ment time as well as assistance of the staff at beam lines 14.1, 14.4, 23.2,
and 29. We thank Dr. Joachim Granzin, Research Center Ju¨lich, for
supplying a fluorescence microscope, and Prof. Dr. Dr. Christian Betzel,
University Hamburg, for giving us the opportunity to use the UV plate
reader he developed.
Author Contributions
Conceived and designed the experiments: JK JL. Performed the
experiments: JK JL. Analyzed the data: JK JL. Contributed reagents/
materials/analysis tools: RS CB. Wrote the paper: JK JL FS. Contributed
to the experimental concept: GB. Critically revised the article for important
intellectual content: GB.
Controlled In Meso Phase Crystallization
PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e35458
References
1. Benvenuti M, Mangani S (2007) Crystallization of soluble proteins in vapor
diffusion for X-ray crystallography. Nature Protoc 2: 1633–1651.
2. McPherson A, Cudney B (2006) Searching for silver bullets: An alternative
strategy for crystallizing macromolecules. J Struct Biol 156: 387–406.
3. Landau EM, Rosenbusch JP (1996) Lipidic cubic phases: A novel concept for the
crystallization of membrane proteins. Proc Natl Acad Sci USA 93:
14532–14535.
4. Pebay-Peyroula E, Rummel G, Rosenbusch JP, Landau EM (1997) X-ray
structure of BR at 2.5 Angstroms from microcrystals grown in lipidic cubic
phases. Science 277: 1676–1681.
5. Qiu H, Caffrey M (2000) The phase diagram of the monoolein/water system:
metastability and equilibrium aspects. Biomaterials 21: 223–234.
6. Cherezov V, Peddi A, Muthusubramaniam L, Zheng YF, Caffrey M (2004) A
robotic system for crystallizing membrane and soluble proteins in lipidic
mesophases. Acta Cryst D 60: 1795–1807.
7. Caffrey M, Cherezov V (2009) Crystallizing membrane proteins using lipidic
mesophases. Nature Protoc 4: 706–731.
8. Cheng A, Hummel B, Caffrey M (1998) A simple mechanical mixer for small
viscous lipid-containing samples. Chem Phys Lipids 95: 11–21.
9. Enstro¨m S, Alfons K, Rasmusson M, Ljusberg-Wahren H (1998) Solvent-
induced sponge (L3) phases in the solvent-monoolein-water system. Prog Coll Pol
Sci S 108: 93–98.
10. Wo¨hri AB, Johansson LC, Wadsten-Hindrichsen P, Wahlgren WY, Fischer G,
et al. (2008) Lipidic-sponge phase screen for membrane protein crystallization.
Structure 16: 1003–1009.
11. Wadsten P, Wo¨hri AB, Snijder A, Katona G, Gardiner AT, et al. (2006) Lipidic
sponge phase crystallization of membrane proteins. J Mol Biol 364: 44–53.
12. Nollert P, Qiu H, Caffrey M, Rosenbusch JP, Landau EM (2001) Molecular
mechanism for the crystallisation of BR in lipidic cubic phases. FEBS Letters
504: 179–186.
13. Kolbe M, Besir H, Essen LO, Oesterhelt D (2000) Structure of the light-driven
chloride pump Halorhodopsin at 1.8 A resolution. Science 288: 1358–1359.
14. Grabe M, Neu J, Oster G, Nollert P (2003) Protein interaction and membrane
geometry. Biophys J 84: 854–868.
15. Luecke H, Schobert B, Richter HT, Cartailler JP, Lanyi JK (1999) Structure of
Bacteriorhodopsin at 1.55 A˚. J Mol Biol 291: 899–911.
16. Michel H (1982) Characterization and crystal packing of three-dimensional BR
crystals. EMBO J 1: 1267–1271.
17. Luecke H, Schobert B, Lanyi JK, Spudich EN, Spudich JL (2001) Crystal
structure of Sensory Rhodopsin II at 2.4 A˚: insights into color tuning and
transducer interaction. Science 293: 1499–1503.
18. Royant A, Nollert P, Edman K, Neutze R, Landau EM, et al. (2001) X-ray
structure of sensory rhodopsin II at 2.1-A˚ resolution. Proc Natl Acad Sci USA
98: 10131–10136.
19. Gordeliy VI, Labahn J, Moukhametzianov R, Efremov R, Granzin J, et al.
(2002) Molecular basis of transmembrane signalling by sensory rhodopsin II-
transducer complex. Nature 419: 484–487.
20. Misquitta Y, Caffrey M (2003) Detergents destabilize the cubic phase of
monoolein: implications for membrane protein crystallization. Biophys J 85:
3084–3096.
21. Misquitta LV, Misquitta Y, Cherezov V, Slattery O, Mohan JM, et al. (2004)
Membrane crystallisation in lipidic cubic meso phases with tailored bilayers.
Structure 12: 2113–2124.
22. Brumshtein B, Greenblatt HM, Futerman AH, Silman I, Sussman JL (2008)
Control of the rate of evaporation in protein crystallization by the microbatch
under oil method. J Appl Cryst 41: 969–971.
23. Chayen NE (1997) A novel technique to control the rate of vapor diffusion,
giving larger protein crystals. J Appl Cryst 30: 198–202.
24. Rassmussen SGF, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, et al.
(2007) Crystal structure of the human beta2 adrenergic G-protein-coupled
receptor. Nature 450: 383–388.
25. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SGF, Thian FS, et al.
(2007) High resolution crystal structure of an engineered human b2-adrenergic
G protein-coupled receptor. Science 318: 1258–1265.
26. Hato M, Yamashita J, Shiono M (2009) Aqueous phase behavior of lipids with
isoprenoid type hydrophobic chains. J Phys Chem B 113: 10196.
27. Misquitta Y, Cherezov V, Havas F, Patterson S, Mohan, et al. (2004) Rational
design of lipid for membrane protein crystallization. J Struct Biol 148: 169–175.
28. Liu W, Hanson M, Stevens R, Cherezov V (2010) LCP-Tm: an assay to measure
and understand stability of membrane proteins in a membrane environment.
Biophys J 98: 1539–1548.
29. Moiseeva ES, Reshetnyak AB, Borshchevsky VI, Baeken C, Bu¨ldt G, et al.
(2008) Comparative analysis of the quality of membrane protein Bacteriorho-
dopsin crystals during crystallization in octylglycoside and octylthioglucoside.
J Surface Invest 3: 29–32.
30. Mironova OS, Efremov RG, Person B, Heberle J, Budayak, et al. (2005)
Functional characterization of sensory rhodopsin II from Halobacterium salinarum
expressed in Escherichia coli. FEBS Lett 579: 3147–3151.
31. Heymann JA, Havelka WA, Oesterhelt D (1993) Homologous overexpression of
a light-driven anion pump in an archaebacterium. Mol Microbiol 7: 623–630.
32. Kors CA, Wallace E, Davies DR, Li L, Laiblea PD, et al. (2009) Effects of
impurities on membrane-protein crystallization in different systems. Acta Cryst D
65: 1062–1073.
33. Caffrey M (2008) On the mechanism of membrane protein crystallization in
lipidic mesophases. Cryst Growth Des 8: 4244–4254.
Controlled In Meso Phase Crystallization
PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e35458
